北京大学学报(医学版) ›› 2019, Vol. 51 ›› Issue (6): 985-988. doi: 10.19723/j.issn.1671-167X.2019.06.001

• 专家笔谈 •    下一篇

低剂量白细胞介素-2在自身免疫性疾病治疗中的意义及前景

何菁,程功,栗占国()   

  1. 北京大学人民医院风湿免疫科,北京大学人民医院风湿免疫研究所,北京 100044
  • 收稿日期:2019-10-25 出版日期:2019-12-18 发布日期:2019-12-19
  • 通讯作者: 栗占国 E-mail:li99@bjmu.edu.cn

  • Received:2019-10-25 Online:2019-12-18 Published:2019-12-19

RICH HTML

  

关键词: 白细胞介素-2, 自身免疫性疾病, 感染

中图分类号: 

  • R593.3

表1

已发表的低剂量IL-2治疗自身免疫性疾病的临床试验"

Diseases Daily dose/(Million IU) Clinical efficacy Immunological changes References
SLE 1 SLEDAI↓ Treg↑,Th17 ↓, Tfh↓,
NK↑,CD56brightNK↑
He et al.(2016,2019)[1,2]
SS 1.5 Not evaluated Treg↑,Th17↓ Miao et al.(2018)[22]
AS 0.5 BASDAI↓ Treg↑,Th17/Treg↓ An et al.(2019)[24]
DM/PM 0.5 CK↓ Treg↑ Zhang et al.(2019)[23]
GVHD 0.3/1/3 per m2 Rash↓ Treg↑ Betts et al.(2017)[15]
Zhao et al.(2016)[16]
HCV-induced vasculitis 1.5 Vasculitis↓ Treg↑,NK↑,CD56brightNK↑ Saadoun et al.(2011)[17]
T1DM 0.33/1/3 Not evaluated Treg↑ Hartemann et al.(2013)[18]
ITP 1 PLT↑ Treg↑ Zhang et al.(2018)[19, 20]
Alopecia areata 1.5 Hair loss area↓ Treg↑,Teff↓ Castela et al.(2014)[21]
11 kinds of autoimmune diseases such as RA 1 Effective Treg↑ Rosenzwajg et al.(2019)[3]

表2

已完成但尚未发表的低剂量IL-2治疗自身免疫性疾病的临床试验"

Disease Year Type Number Country
RA 2016 Single-center 47 China
SS 2016 Single-center 60 China
Multiple sclerosis 2016 Single-center 30 France
Hemolytic anemia 2017 Single-center 2 France
CKD 2016 Single-center 10 China
SLE 2017 Multi-center 100 France etc.
Amyotrophic lateral sclerosis 2015 Single-center 36 France
[1] He J, Zhang R, Shao M , et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: A randomised, double-blind, placebo-controlled trial[J/OL]. Ann Rheum Dis, 2019, 9(2019-09-19)[2019-10-01]. .
[2] He J, Zhang X, Wei Y , et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus[J]. Nat Med, 2016,22(9):991-993.
[3] Rosenzwajg M, Lorenzon R, Cacoub P , et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial[J]. Ann Rheum Dis, 2019,78(2):209-217.
[4] Morgan DA, Ruscetti FW, Gallo R . Selective in vitro growth of T lymphocytes from normal human bone marrows[J]. Science, 1976,193(4257):1007-1008.
[5] Mizel SB, Farrar JJ . Revised nomenclature for antigen-nonspecific T-cell proliferation and helper factors[J]. Cell Immunol, 1979,48(2):433-436.
[6] Shao Q, Gao H,. Progress in interleukin-2 therapy for rheumatic immune diseases by regulating the immune balance of T cells[J/OL]. Scand J Immunol, 2019, 9(2019-09-08)[2019-10-01].
[7] Sakaguchi S, Wing K, Miyara M . Regulatory T cells: A brief history and perspective[J]. Eur J Immunol, 2007,37(Suppl 1):116-123.
[8] Harrington LE, Hatton RD, Mangan PR , et al. Interleukin 17-producing CD4+effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages [J]. Nat Immunol, 2005,6(11):1123-1132.
[9] Zhao Z, Zhang X, Su L , et al. Fine tuning subsets of CD4+T cells by low-dosage of IL-2 and a new therapeutic strategy for autoimmune diseases [J]. Int Immunopharmacol, 2018,56:269-276.
[10] Kim HS, Jang SW, Lee W , et al. PTEN drives Th17 cell differentiation by preventing IL-2 production[J]. J Exp Med, 2017,214(11):3381-3398.
[11] Osnes LT, Nakken B, Bodolay E , et al. Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and pri-mary immunodeficiencies: Novel tool for diagnostics and patient follow-up[J]. Autoimmun Rev, 2013,12(10):967-971.
[12] Li J, Lu E, Yi T , et al. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells[J]. Nature, 2016,533(7601):110-114.
[13] Shao M, He J, Zhang R , et al. Interleukin-2 deficiency associated with renal impairment in systemic lupus erythematosus[J]. J Interferon Cytokine Res, 2019,39(2):117-124.
[14] Shin MS, Lee N, Kang I . Effector T-cell subsets in systemic lupus erythematosus: Update focusing on Th17 cells[J]. Curr Opin Rheumatol, 2011,23(5):444-448.
[15] Betts BC, Pidala J, Kim J , et al. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation[J]. Haematologica, 2017,102(5):948-957.
[16] Zhao XY, Zhao XS, Wang YT , et al. Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study[J]. Oncoimmunology, 2016,5(12):e1250992.
[17] Saadoun D, Rosenzwajg M, Joly F , et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis[J]. N Engl J Med, 2011,365(22):2067-2077.
[18] Hartemann A, Bensimon G, Payan CA , et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial[J]. Lancet Diabetes Endocrinol, 2013,1(4):295-305.
[19] Zhang J, Ruan Y, Shen Y , et al. Low dose IL-2 increase regulatory T cells and elevate platelets in a patient with immune thrombocytopenia[J]. Cytometry B Clin Cytom, 2018,94(3):400-404.
[20] Zhang J, Ruan Y, Xu X , et al. Therapeutic potential of low-dose IL-2 in immune thrombocytopenia: An analysis of 3 cases[J]. Cytom B Clin Cytom, 2018,94(3):428-433.
[21] Castela E, Le Duff F, Butori C , et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata[J]. JAMA Dermatol, 2014,150(7):748-751.
[22] Miao M, Hao Z, Guo Y , et al. Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with pri-mary Sjögren’s syndrome[J]. Ann Rheum Dis, 2018,77(12):1838-1840.
[23] Zhang S, Wang J, Sun H , et al. Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2[J/OL]. Ann Rheum Dis, 2019, 10(2019-10-14)[2019-10-16].
[24] An H, Li X, Li F , et al. The absolute counts of peripheral T lymphocyte subsets in patient with ankylosing spondylitis and the effect of low-dose interleukin-2[J]. Medicine (Baltimore), 2019,98(15):e15094.
[1] 金江, 陈雪, 赵琰, 贾军, 张建中. 卵清蛋白诱导的特应性皮炎小鼠模型中白细胞介素-25的作用及其调控意义[J]. 北京大学学报(医学版), 2024, 56(5): 756-762.
[2] 乔佳佳,田聪,黄晓波,刘军. 肾结石合并系统性红斑狼疮行经皮肾镜碎石取石术的安全性和有效性评估[J]. 北京大学学报(医学版), 2024, 56(4): 745-749.
[3] 朱金荣,赵亚娜,黄巍,赵微微,王悦,王松,苏春燕. 感染新型冠状病毒的血液透析患者的临床特征[J]. 北京大学学报(医学版), 2024, 56(2): 267-272.
[4] 刘鑫,石雪迎,李军. 新型冠状病毒感染相关缺血性结肠炎1例[J]. 北京大学学报(医学版), 2024, 56(2): 362-365.
[5] 王丽芳,石连杰,宁武,高乃姝,王宽婷. 干燥综合征合并冷凝集素病1例[J]. 北京大学学报(医学版), 2023, 55(6): 1130-1134.
[6] 张陈光,陈旭岩,吴圣,冯莉莉,王琰,陈妤,段敏,王科,宋琳琳. 咽旁脓肿致颈内动脉假性动脉瘤1例[J]. 北京大学学报(医学版), 2023, 55(6): 1135-1138.
[7] 乔婕,芦丽霞,何玉婷,门春翠,楚新新,武蓓,赵慧萍,王梅. 真菌性腹膜透析导管出口感染合并隧道感染1例[J]. 北京大学学报(医学版), 2023, 55(4): 748-754.
[8] 林浩,李菁华,杨潇,陈晓婷,史宇晖,常春,郝元涛,曹望楠. 中国成都男男性行为人群HIV暴露前预防用药行为-认知偏差现状及其影响因素[J]. 北京大学学报(医学版), 2023, 55(3): 511-520.
[9] 王哲,孙伟,杨雪,宋颖,姬爱平,白洁. 口腔急诊颌面部感染患者临床分析[J]. 北京大学学报(医学版), 2023, 55(3): 543-547.
[10] 叶一林,刘恒,潘利平,柴卫兵. 全膝关节置换术后假体周围痛风发作误诊1例[J]. 北京大学学报(医学版), 2023, 55(2): 362-365.
[11] 曹芳,钟明,刘从容. 宫体POLE突变型内膜样癌合并HPV感染相关性宫颈腺癌1例报道及文献回顾[J]. 北京大学学报(医学版), 2023, 55(2): 370-374.
[12] 俞光岩,宿骞,张艳,吴立玲. 唾液腺疾病与全身系统性疾病的相关性[J]. 北京大学学报(医学版), 2023, 55(1): 1-7.
[13] 邢晓燕,张筠肖,朱冯赟智,王一帆,周新尧,李玉慧. 皮肌炎合并巨噬细胞活化综合征5例[J]. 北京大学学报(医学版), 2022, 54(6): 1214-1218.
[14] 徐朝焰,林长艺,叶达梅,吴培埕,宋明辉,刘有添,邓琼,黄雪艳,范忠晓,游雪兰. 感染性关节炎诊断分析[J]. 北京大学学报(医学版), 2022, 54(6): 1234-1237.
[15] 康志宇,王磊磊,韩永正,郭向阳. 北京冬季奥林匹克运动会运动员手术的麻醉管理[J]. 北京大学学报(医学版), 2022, 54(4): 770-773.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!